Novo Nordisk Intensifies Lobbying Efforts in Push for Medicare Coverage of Obesity Medications
Novo Nordisk, the manufacturer of the weight loss drug Wegovy as well as the diabetes medication Ozempic, spent lavishly on federal lobbying in the first half of 2023. The Danish pharmaceutical company is urging Congress to approve a bill that would eliminate Medicare coverage restrictions for weight management treatments. In the past three months, Novo […]